Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stage Information for NSCLC
BackgroundIn NSCLC, the determination of stage is important in terms of therapeutic and prognostic implications. Careful initial diagnostic evaluation to define the location and to determine the extent of primary and metastatic tumor involvement is critical for the appropriate care of patients. In general, symptoms, physical signs, laboratory findings, or perceived risk of distant metastasis lead to an evaluation for distant metastatic disease. Additional tests such as bone scans and computed tomography (CT)/magnetic resonance imaging (MRI) of the brain may be performed if initial assessments suggest metastases or if patients with stage III disease are under consideration for aggressive local and combined modality treatments.Stage has a critical role in the selection of therapy. The stage of disease is based on a combination of clinical factors and pathological factors. The distinction
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (02 / 27 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of the EvidenceAdded Spira et al. as reference 4.Added Lissowska et al. as reference 23.Added Straif et al. as reference 27.Added Gray et al. as reference 32.Added text evidence indicating an association between constituents of ambient air pollution and increased lung cancer mortality continues to strengthen, with reports from Asia and New Zealand documenting increased risks with exposure to measures of particulate matter, sulfur dioxide, and nitrogen dioxide (cited Katanoda et al., Cao et al., and Hales et al. as references 37, 38, and 39, respectively).Added World Cancer Research Fund/American Institute for Cancer Research as reference 40.This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stages IA and IB NSCLC Treatment
Standard Treatment Options for Stages IA and IB NSCLCStandard treatment options for stage IA NSCLC and IB NSCLC include the following:Surgery.Radiation therapy.Chemotherapy and radiation therapy have not been shown to improve outcomes in stage I NSCLC that has been completely resected.SurgerySurgery is the treatment of choice for patients with stage I NSCLC. A lobectomy or segmental, wedge, or sleeve resection may be performed as appropriate. Patients with impaired pulmonary function are candidates for segmental or wedge resection of the primary tumor. Careful preoperative assessment of the patient's overall medical condition, especially the patient's pulmonary reserve, is critical in considering the benefits of surgery. The immediate postoperative mortality rate is age related, but a 3% to 5% mortality rate with lobectomy can be expected.Evidence (surgery):The Lung Cancer Study Group conducted a randomized study (LCSG-821) that compared lobectomy
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Recurrent Malignant Mesothelioma
Treatment of patients with recurrent mesothelioma usually utilizes procedures and/or agents not previously employed in the initial treatment attempt. No standard treatment approaches have been proven to improve survival or control symptoms for a prolonged period of time. These patients should be considered candidates for phase I and II clinical trials evaluating new biologicals, chemotherapeutic agents, or physical approaches.[1,2,3,4,5,6] Patients with recurrent mesothelioma who have not received prior chemotherapy are candidates for first-line chemotherapy with cisplatin pemetrexed or cisplatin raltitrexed. (Refer to the Advanced Malignant Mesothelioma (Stages II, III, and IV) section of this summary.) However, patients with recurrent mesothelioma who receive surgery, or at least do not receive chemotherapy as part of the primary treatment and recur subsequently, are candidates for chemotherapy.A large, randomized study compared pemetrexed to best supportive care in 243 patients who
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Description of the Evidence
BackgroundIncidence and mortalityLung cancer is the most commonly occurring noncutaneous cancer in men and women combined in the United States and is the leading cause of cancer deaths. In 2013 alone, it is estimated that there will be 228,190 new cases diagnosed, and 72,220 women and 87,260 men will die from this disease. The lung cancer death rate rose rapidly over several decades in both sexes, with a persistent decline for men commencing in 1991. From 2005 to 2009, death rates decreased by 2.8% per year in men and by 1.0% per year in women.Risk factorsTobacco use, second hand smoke, and other risk factorsThe most important risk factor for lung cancer (as for many other cancers) is tobacco use.[2,3] Cigarette smoking has been definitively established by epidemiologic and preclinical animal experimental data as the primary cause of lung cancer. This causative link has been widely recognized since the 1960s, when national reports in Great Britain and the United
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - To Learn More About Small Cell Lung Cancer
For more information from the National Cancer Institute about small cell lung cancer, see the following:Lung Cancer Home PageWhat You Need to Know About™ Lung CancerLung Cancer PreventionLung Cancer ScreeningDrugs Approved for Small Cell Lung CancerSmoking Home Page (Includes help with quitting)Cigarette Smoking: Health Risks and How to QuitSmoking in Cancer CareSecondhand Smoke and CancerFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - What is screening?
Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early,it may be easier to treat. By the time symptoms appear,cancer may have begun to spread. Scientists are trying to better understand which people are more likely to get certain types of cancer. They also study the things we do and the ...
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062824-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Lung Cancer Prevention